Fig. 5.
PBPK simulations of fasted PK profiles of efavirenz (a, b) and digoxin (c, d). a Efavirenz 600 mg oral administration simulated with measured FaSSIF solubility. b Efavirenz 600 mg oral administration simulated with optimized (red line) and maximum solubility (blue line). c Digoxin 1 mg oral administration simulated with measured FaSSIF solubility. d Digoxin 1 mg oral administration simulated with optimized (red line) and maximum solubility (blue line), in this case, overlapped. FaSSIF fasted state simulated intestinal fluid.
